İlaç İlişkili Çene Osteonekrozu (MRONJ): Güncel Tanım ve Klinik Özellikler

Weinerman S, Usera GL. Antiresorptive Therapies for Osteoporosis. Manag Medicat-Relat Osteonecrosis Jaw Issue Oral Maxillofac Clin N Am 27-4 Manag Medicat-Relat Osteonecrosis Jaw Issue Oral Maxillofac Clin N Am 27-4. 2016;27(4):555.

Mehrotra B. Antiresorptive therapies for the treatment of malignant osteolytic bone disease. Oral Maxillofac Surg Clin. 2015;27(4):561-6.

Mosaico G, Casu C. Management and maintenance of oral health: Personalized primary prevention strategies and protocols in patients at risk of developing medication-related osteonecrosis of the jaw. INNOSC Theranostics Pharmacol Sci. 2024;7(1):1419.

AlRowis R, Aldawood A, AlOtaibi M, Alnasser E, AlSaif I, Aljaber A, vd. Medication-related osteonecrosis of the jaw (MRONJ): a review of pathophysiology, risk factors, preventive measures and treatment strategies. Saudi Dent J. 2022;34(3):202-10.

Khan AA, Morrison A, Kendler DL, Rizzoli R, Hanley DA, Felsenberg D, vd. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. J Clin Densitom. 01 Ocak 2017;20(1):8-24. doi:10.1016/j.jocd.2016.09.005

Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, vd. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. J Oral Maxillofac Surg. 01 Ekim 2014;72(10):1938-56. doi:10.1016/j.joms.2014.04.031

Mavrokokki T, Cheng A, Stein B, Goss A. Nature and Frequency of Bisphosphonate-Associated Osteonecrosis of the Jaws in Australia. J Oral Maxillofac Surg. 01 Mart 2007;65(3):415-23. doi:10.1016/j.joms.2006.10.061

Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 Update. J Oral Maxillofac Surg. 01 Mayıs 2022;80(5):920-43. doi:10.1016/j.joms.2022.02.008

Jeon HL, Oh IS, Baek YH, Yang H, Park J, Hong S, vd. Zoledronic acid and skeletal-related events in patients with bone metastatic cancer or multiple myeloma. J Bone Miner Metab. Mart 2020;38(2):254-63. doi:10.1007/s00774-019-01052-6

Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, vd. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 01 Mayıs 2012;23(5):1341-7. doi:10.1093/annonc/mdr435

Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, vd. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458-68. doi:10.1093/jnci/94.19.1458

Stopeck A, Brufsky A, Kennedy L, Bhatta S, Bhowmik D, Buchanan J, vd. Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ. 02 Ocak 2020;23(1):37-47. doi:10.1080/13696998.2019.1651122

Delmas PD. The use of bisphosphonates in the treatment of osteoporosis. Curr Opin Rheumatol. 2005;17(4):462-6. doi:10.1097/01.bor.0000163448.51661.87

Gossiel F, Paggiosi MA, Naylor KE, McCloskey EV, Walsh J, Peel N, vd. The effect of bisphosphosphonates on bone turnover and bone balance in postmenopausal women with osteoporosis: The T-score bone marker approach in the TRIO study. Bone. 2020;131:115158.

Watts NB. Bisphosphonate treatment of osteoporosis. Clin Geriatr Med. 01 Mayıs 2003;19(2):395-414. doi:10.1016/S0749-0690(02)00069-1

Boyce AM, Kelly MH, Brillante BA, Kushner H, Wientroub S, Riminucci M, vd. A Randomized, Double Blind, Placebo-Controlled Trial of Alendronate Treatment for Fibrous Dysplasia of Bone. J Clin Endocrinol Metab. 01 Kasım 2014;99(11):4133-40. doi:10.1210/jc.2014-1371

Hanley DA, Adachi JD, Bell A, Brown V. Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract. Aralık 2012;66(12):1139-46. doi:10.1111/ijcp.12022

Apland K. Comparing Prevalence of Medication-Related Osteonecrosis of the Jaw (MRONJ) due to Denosumab and Bisphosphonates as a Side Effect of Osteoporosis Treatment [İnternet]. 2018 [a.yer 12 Şubat 2026]. Erişim adresi: https://commons.und.edu/pas-grad-papers/2/

Paula FJA de, Black DM, Rosen CJ. Osteoporosis and bone biology. Williams Textb Endocrinol [Internet]. 2016 [a.yer 12 Şubat 2026]. Erişim adresi: https://repositorio.usp.br/item/002830213

Rosen HN. The use of bisphosphonates in postmenopausal women with osteoporosis. UpToDate. 2017.

Campisi G, Mauceri R, Bertoldo F, Bettini G, Biasotto M, Colella G, vd. Medication-related osteonecrosis of jaws (MRONJ) prevention and diagnosis: Italian consensus update 2020 [İnternet]. MDPI; 2020 [a.yer 23 Şubat 2026]. Erişim adresi: https://www.mdpi.com/1660-4601/17/16/5998

Steinberg M, Hayken G, Steinberg D. A quantitative system for staging avascular necrosis. J Bone Joint Surg Br. Ocak 1995;77-B(1):34-41. doi:10.1302/0301-620X.77B1.7822393

Fleisher KE, Welch G, Kottal S, Craig RG, Saxena D, Glickman RS. Predicting risk for bisphosphonate-related osteonecrosis of the jaws: CTX versus radiographic markers. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontology. 01 Ekim 2010;110(4):509-16. doi:10.1016/j.tripleo.2010.04.023

Fedele S, Porter SR, D’Aiuto F, Aljohani S, Vescovi P, Manfredi M, vd. Nonexposed Variant of Bisphosphonate-associated Osteonecrosis of the Jaw: A Case Series. Am J Med. 01 Kasım 2010;123(11):1060-4. doi:10.1016/j.amjmed.2010.04.033

Fleisher KE, Janal MN, Albstein N, Young J, Bikhazi V, Schwalb S, vd. Comorbid conditions are a risk for osteonecrosis of the jaw unrelated to antiresorptive therapy. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019;127(2):140-50.

Calhoun KH, Shapiro RD, Stiernberg CM, Calhoun JH, Mader JT. Osteomyelitis of the Mandible. Arch Otolaryngol Neck Surg. 01 Ekim 1988;114(10):1157-62. doi:10.1001/archotol.1988.01860220091031

Liao MT, Chien WC, Wang JC, Chung CH, Chu SJ, Tsai SH. Increased risk of bisphosphonate-related osteonecrosis of the jaw in patients with Sjögren’s syndrome: nationwide population-based cohort study [Internet]. 01 Şubat 2019. doi:10.1136/bmjopen-2018-024655

Bacci C, Cerrato A, Bardhi E, Frigo AC, Djaballah SA, Sivolella S. A retrospective study on the incidence of medication-related osteonecrosis of the jaws (MRONJ) associated with different preventive dental care modalities. Support Care Cancer. Şubat 2022;30(2):1723-9. doi:10.1007/s00520-021-06587-x

Drudge-Coates L, Van den Wyngaert T, Schiødt M, Van Muilekom HAM, Demonty G, Otto S. Preventing, identifying, and managing medication-related osteonecrosis of the jaw: a practical guide for nurses and other allied healthcare professionals. Support Care Cancer. 2020;28(9):4019-29.

Otto S, Pautke C, Van den Wyngaert T, Niepel D, Schiødt M. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev. 2018;69:177-87.

Mauceri R, Coniglio R, Abbinante A, Carcieri P, Tomassi D, Panzarella V, vd. The preventive care of medication-related osteonecrosis of the jaw (MRONJ): a position paper by Italian experts for dental hygienists. Support Care Cancer. Ağustos 2022;30(8):6429-40. doi:10.1007/s00520-022-06940-8

Sturrock A, Preshaw PM, Hayes C, Wilkes S. General dental practitioners’ perceptions of, and attitudes towards, improving patient safety through a multidisciplinary approach to the prevention of medication-related osteonecrosis of the jaw (MRONJ): a qualitative study in the North East of England. BMJ Open. 2019;9(6):e029951.

Rückschloß T, Moratin J, Zittel S, Pilz M, Roser C, Engel M, vd. Influence of preventive tooth extractions on quality of life in patients with antiresorptive intake—a prospective longitudinal study. Int J Environ Res Public Health. 2021;18(21):11650.

Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F, vd. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3-23.

Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, vd. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg. 2014;72(10):1938-56.

Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, vd. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg. 2014;72(10):1938-56.

Coropciuc R, Moreno-Rabié C, De Vos W, Van De Casteele E, Marks L, Lenaerts V, vd. Navigating the complexities and controversies of medication-related osteonecrosis of the jaw (MRONJ): a critical update and consensus statement. Acta Chir Belg. 02 Ocak 2024;124(1):1-11. doi:10.1080/00015458.2023.2291295

Sacco R, Woolley J, Patel G, Calasans-Maia MD, Yates J. Systematic review of medication related osteonecrosis of the jaw (MRONJ) in patients undergoing only antiangiogenic drug therapy: surgery or conservative therapy? Br J Oral Maxillofac Surg. 01 Şubat 2022;60(2):e216-30. doi:10.1016/j.bjoms.2021.03.006

Keyes D, Turfe H, Das JM. Prevention Strategies. Içinde: StatPearls [Internet] [Internet]. StatPearls Publishing; 2025 [a.yer 23 Şubat 2026]. Erişim adresi: https://www.ncbi.nlm.nih.gov/sites/books/NBK537222/ PubMed PMID: 30725907.

Mauceri R, Coppini M, Attanasio M, Bedogni A, Bettini G, Fusco V, vd. MRONJ in breast cancer patients under bone modifying agents for cancer treatment-induced bone loss (CTIBL): a multi-hospital-based case series. BMC Oral Health. 04 Şubat 2023;23(1):71. doi:10.1186/s12903-023-02732-6

Steel B. Management of Medication-related Osteonecrosis of the Jaw (MRONJ) risk in patients due to commence anti-resorptive/anti-angiogenic drugs – how should pre-drug-treatment dental preventive care be organised? Community Dent Health. 2019;(36):244-54. doi:10.1922/CDH_4582Steel11

Sturrock A, Preshaw PM, Hayes C, Wilkes S. General dental practitioners’ perceptions of, and attitudes towards, improving patient safety through a multidisciplinary approach to the prevention of medication-related osteonecrosis of the jaw (MRONJ): a qualitative study in the North East of England. BMJ Open. 2019;9(6):e029951.

Campisi G. New paradigms for dental prevention of medication related osteonecrosis of jaws (MRONJ). Qeios [İnternet]. 2018 [a.yer 23 Şubat 2026]. Erişim adresi: https://pdfs.semanticscholar.org/8784/21f9add8febde26fa30d35bd0e0e4e581700.pdf

Chan BH, Yee R, Puvanendran R, Ang SB. Medication-related osteonecrosis of the jaw in osteoporotic patients: prevention and management. Singapore Med J. 2018;59(2):70.

Otto S, Pautke C, Van den Wyngaert T, Niepel D, Schiødt M. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev. 2018;69:177-87.

Drudge-Coates L, Van Den Wyngaert T, Schiødt M, Van Muilekom HAM, Demonty G, Otto S. Preventing, identifying, and managing medication-related osteonecrosis of the jaw: a practical guide for nurses and other allied healthcare professionals. Support Care Cancer. Eylül 2020;28(9):4019-29. doi:10.1007/s00520-020-05440-x

Ali IE, Sumita Y. Medication-related osteonecrosis of the jaw: Prosthodontic considerations. Jpn Dent Sci Rev. 2022;58:9-12.

Miranda M, Gianfreda F, Raffone C, Antonacci D, Pistilli V, Bollero P. The Role of Platelet‐Rich Fibrin (PRF) in the Prevention of Medication‐Related Osteonecrosis of the Jaw (MRONJ). Scribante A, editör. BioMed Res Int. Ocak 2021;2021(1):4948139. doi:10.1155/2021/4948139

Teślak M, Chlebus I, Ordyniec-Kwaśnica I. The role of interdisciplinary cooperation in the prevention of medication-related osteonecrosis of the jaw (MRONJ). Eur J Transl Clin Med. 2020;3(1):60-5.

Tetradis S, Allen MR, Ruggiero SL. Pathophysiology of Medication-Related Osteonecrosis of the Jaw—A Minireview. J Bone Miner Res Plus. 2023;7(8):e10785.

Thomas JG, Ouanounou A. Medication-related osteonecrosis of the jaw: a narrative review of risk factors, diagnosis, and management. Front Oral Maxillofac Med [İnternet]. 2023 [a.yer 23 Şubat 2026];5. Erişim adresi: https://fomm.amegroups.org/article/view/63019/html

Thornhill MH, Lockhart PB, Prendergast B, Chambers JB, Shanson D. NICE and antibiotic prophylaxis to prevent endocarditis. Br Dent J. 2015;218(11):619-21.